Jessica Hopfield, PhD, is a healthcare strategist and investor focused on bringing biotech and medical device innovation to patients. Her firm, J Hopfield Consulting, provides strategic guidance and capital to start-up technology firms seeking to commercialize intellectual property. She served as the Chair of Joslin’s Board of Trustees from 2015 to 2019.
Jessica serves as an Independent Director of Insulet Corporation, a global medical device company that manufactures and sells the Omnipod(r) insulin patch pump and partners with pharmaceutical companies to deliver subcutaneous drugs. She serves on the Board of Directors of Editas Medicine, a leading genome editing company, focused on translating the power and potential of CRISPR genome editing systems into treatments for people living with serious disease. She also serves on the Board of Directors of Maravai (MRVI), a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines.
Jessica is a former partner of McKinsey & Company in their Global Pharmaceutical and Medical Device practice. While at McKinsey from 1995-2009, she helped clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. She previously held management positions at Merck Sharp and Dohme in Clinical Development, Outcomes Research, and Marketing.
Jessica earned an MBA from Harvard Graduate School of Business Administration as a Baker Scholar, a PhD in neuroscience/biochemistry from Rockefeller University, and a BS from Yale College.